Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial

Bevers, Lisanne A H;Toledo, Gabriela;Kisekka, Muzamil;Kaudha, Elizabeth;Ahimbisibwe, Grace M;Deprez, Isabelle;Arumugan, Tiyara;Variava, Ebrahim;Violari, Avy;White, Iona;Bbuye, Dickson;Nanduudu, Annet;Mulwanyi, Enoch;Amuge, Pauline;Rutebarika, Diana A;Kekitiinwa, Adeodata;Kityo, Cissy;Musoke, Philippa;Archary, Moherndran;Boles, Justine;Thomason, Margaret J;de Wildt, Saskia N;Giaquinto, Carlo;Colbers, Angela;Burger, David M;Buchanan, Ann M;Chan, Man K;Jacobs, Tom G;Turkova, Anna

2025